Home / Healthcare / Competitor Analysis: Targeted Therapy of Hepatitis C

Competitor Analysis: Targeted Therapy of Hepatitis C

By: La Merie Publishing
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
 
Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-α administered is dependent on the type used.
 
The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life.
 
The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:
 
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information. 
 
Index
 
  • HCV Protease Inhibitors
  • HCV RNA Polymerase Inhibitors
  • Cyclophilin Inhibitors
  • HCV NS5A Protein Inhibitors
  • HCV NS4B-RNA Binding Inhibitors
  • Therapeutic & Preventative HCV Vaccines
  • Therapeutic HCV Antibodies
  • HCV Viral Entry Inhibitors
  • HCV Replication Inhibitors
  • Novel Mechanism of Action HCV Virus & Host Cell Targets
  • TLR Agonists
  • Various
  • Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
  • About La Merie
 
Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
 
Abbott
Achillion Pharmaceuticals
Alios Biopharma
Altor Biosciences
Anadys Pharmaceuticals
Astex Therapeutics
Avila Therapeutics
Bionor Immuno
Biotica Technology
Biotron
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
C-Pharma
Can-Fite BioPharma
Chimerix
ChronTech Pharma
Compass Biotechnologies
Conatus Pharmaceuticals
CureTech
Cytheris
Debiopharm
Dynavax Technologies
Eiger Pharmaceuticals
Enanta Pharmaceuticals
Epiphany Biosciences
Epixis
Genmab
GenPhar
Gilead Sciences
GlaxoSmithKline (GSK)
GlobeImmune
Heat Biologics
Idenix Pharmaceuticals
Idera Pharmaceuticals
Inhibitex
Inovio
Intellektualniy Dialog
Intercell
iTherX Pharmaceuticals
Japan Tobacco
Johnson & Johnson (J&J)
Medivir
Massachusetts Biologic Laboratories (MBL)
Merck & Co
Mitsubishi Tanabe Pharma
Morningside Asia Venture
Novartis
Okairos
Ono Pharmaceutical
Paladin Biosciences
Peregrine Pharmaceuticals
Pfizer
Pharmasset
PTC Therapeutics
Presidio Pharmaceuticals
Progenics Pharmaceuticals
Regulus Therapeutics
Replicor
Roche
Rosetta Genomics
Samaritan Pharmaceuticals
Santaris Pharma
SCYNEXIS
Tacere Therapeutics
TaiGen Biotechnology
Teva Pharmaceutical Industries
Theravance
Transgene
Tripep
Vertex Pharmaceuticals
Viriome
Virionics
ViroBay
 
About Competitor Analysis Series:
 
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

NA

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +